시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 암 항체약물접합체(ADC) 시장 보고서(2025년)
Cancer Antibody Drug Conjugates Global Market Report 2025
상품코드 : 1889321
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,505,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,403,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,301,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

암 항체약물접합체(ADC) 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 81억 9,000만 달러로 평가되었고, 2025년에는 91억 7,000만 달러에 달할 것으로 추정되며, CAGR 11.9%로 성장이 전망되고 있습니다. 지난 수년간의 성장은 세계의 암 발생률 상승, 선진국의 헬스케어 지출 증가, 표적 치료법에 대한 수요 증가, 정밀의료의 임상 이용 급증, 암 치료 보험의 적용 범위 확대, 조기 암 검진에 대한 의식 향상에 기인한 것으로 보입니다.

암 항체약물접합체(ADC) 시장 규모는 향후 수년간 급속한 성장이 예상됩니다. 2029년에는 141억 7,000만 달러에 달할 것으로 예측되며, CAGR 11.5%로 성장할 전망입니다. 예측 기간에 있어서의 성장 요인으로서는 개별화 암 치료에 대한 선호 고조, 정부에 의한 종양학 조사 프로그램에 대한 투자 증가, 화학요법의 부작용 경감에 대한 주목의 고조, 차세대 암 치료제를 향한 제약 기업 간 제휴 급증, 신흥국에서 암 검진 시책 확대, 전문 종양 클리닉의 보급 확대 등을 들 수 있습니다. 예측 기간 주요 동향으로는 종양 특이적 항체 표적화 기술 진보, 링커 안정성 및 페이로드 전달 기술의 혁신, 동반진단 통합의 진전, 이중 특이성 항체 공학의 개발, 면역 자극성 컨쥬게이트에 관한 연구 개발, 페이로드 다양화 기술의 발전 등을 들 수 있습니다.

암 이환율의 상승은 향후 암 항체약물접합체 시장의 성장을 가속할 것으로 예측됩니다. 암 이환율이란 특정 시점에서 새롭게 진단된 분과 과거에 진단된 분을 맞춘 암 경력이 있는 생존자의 총수를 말합니다. 부적절한 식생활, 흡연, 음주, 환경오염물질에 대한 노출 등 생활습관과 관련된 위험에 의해 다양한 암을 발병할 위험성이 높아지고 있기 때문에 암 이환율은 증가하는 경향이 있습니다. 항체약물접합체는 강력한 화학요법제를 암세포에 직접 전달함으로써 건강한 조직에 대한 손상을 최소화하면서 암 치료를 지원합니다. 특정 종양 항원을 표적으로 함으로써 치료 정밀도를 높이고 치료 효과를 향상시키며, 환자의 부작용을 경감합니다. 예를 들어, 호주 정부 기관인 Cancer Australia에 따르면 2025년 2월 시점에서 2024년 신규 췌장암 증례 수는 4,641건(남성 2,414건, 여성 2,227건)이었습니다. 따라서 암 유병률의 상승이 암 항체약물접합체 시장의 성장을 견인하고 있습니다.

암 항체약물접합체 시장에서 사업을 전개하는 주요 기업은 표적 전달성, 치료 정밀도, 안전성을 높이기 위해 절단 가능한 종양 활성화 링커 기술 등 기술적으로 첨단 솔루션의 개발에 주력하고 있습니다. 절단 가능한 종양 활성화 링커 기술은 항체약물접합체에서 세포독성 약물을 항체에 결합시키고 항체약물접합체가 종양 미세환경에 도달할 때만 약물을 방출하는 특수 화학 시스템을 말합니다. 예를 들어, 2025년 6월에는 일본의 바이오 의약품 기업인 다이이치 산쿄 주식회사가 미국 식품의약국(FDA)으로부터 Datroway(다토포타마브 델쿠스테칸 DLNK)의 승인을 취득했습니다. 이는 절단가능한 링커를 이용한 트로포블라스트 세포 표면 항원 2(TROP2)를 표적으로 하는 항체약물접합체이며, EGFR 돌연변이 양성의 비소세포 폐암(NSCLC)으로, 국소 진행성 또는 전이성이며, EGFR 표적 치료 및 백금계 화학요법의 기왕력이 있는 성인 환자를 대상으로 하고 있습니다. 본 제품은 표적 지향성 페이로드 방출, 방관자 효과를 포함한 종양 세포 살상능의 향상, 치료 내성의 강화를 특징으로 합니다. 약물 전달의 정확성을 높이고 치료가 어려운 고형 종양에 대한 치료 옵션을 확장합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Cancer antibody drug conjugates are targeted biopharmaceuticals made of monoclonal antibodies connected to powerful cytotoxic drugs. These antibodies selectively attach to cancer cell antigens, delivering the drug directly to malignant cells while limiting damage to healthy tissues. This targeted method improves treatment effectiveness, reduces side effects, and offers new therapeutic options for patients with cancers that do not respond to standard therapies.

The main types of antibodies used in cancer drug conjugates include monoclonal antibodies, bispecific antibodies, low molecular weight antibodies, and polyclonal antibodies. Monoclonal antibodies are laboratory produced molecules designed to accurately identify and bind to specific antigens on target cells, allowing targeted therapeutic action. The different mechanisms of action involved are cell death signal inducers, microtubule disruptors, deoxyribonucleic acid damage inducers, and immune checkpoint inhibitors, and they use technologies such as cleavable linkers and non cleavable linkers. These drug conjugates are indicated for breast cancer, blood cancer, lung cancer, gastrointestinal cancer, and prostate cancer, and they serve several end users, including hospitals, specialty clinics, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The cancer antibody drug conjugates market research report is one of a series of new reports from The Business Research Company that provides cancer antibody drug conjugates market statistics, including the cancer antibody drug conjugates industry global market size, regional shares, competitors with the cancer antibody drug conjugates market share, detailed cancer antibody drug conjugates market segments, market trends, and opportunities, and any further data you may need to thrive in the cancer antibody drug conjugates industry. This cancer antibody drug conjugates market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer antibody drug conjugates market size has grown rapidly in recent years. It will grow from $8.19 billion in 2024 to $9.17 billion in 2025 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to rising incidence of cancer worldwide, increasing healthcare spending in developed nations, growing demand for targeted treatment options, surge in clinical use of precision therapies, expansion of oncology insurance coverage, and rising awareness of early cancer detection.

The cancer antibody drug conjugates market size is expected to see rapid growth in the next few years. It will grow to $14.17 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising preference for personalized cancer therapies, increasing investment in oncology research programs by governments, growing focus on reducing chemotherapy side effects, surge in pharmaceutical collaborations for next generation cancer therapeutics, expansion of cancer screening initiatives in emerging economies, and rising penetration of specialty oncology clinics. Major trends in the forecast period include technological advancements in tumor specific antibody targeting, innovations in linker stability and payload delivery, advancements in companion diagnostic integration, developments in bispecific antibody engineering, research and development in immune stimulating conjugates, and technological progress in payload diversification.

The rising prevalence of cancer is expected to propel the growth of the cancer antibody drug conjugates market going forward. Prevalence of cancer refers to the total number of people, both newly diagnosed and previously diagnosed, who are alive with a history of cancer at a specific point in time. The prevalence of cancer is increasing due to lifestyle related risks such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, elevating the risk of developing various cancers. Cancer antibody drug conjugates aid in cancer treatment by delivering potent chemotherapy drugs directly to cancer cells, minimizing harm to healthy tissues. They enhance treatment precision by targeting specific tumor antigens, improving therapeutic effectiveness and reducing side effects for patients. For instance, in February 2025, according to Cancer Australia, an Australia based government agency, there were 4641 new pancreatic cancer cases in 2024, with 2414 in males and 2227 in females. Therefore, the rising prevalence of cancer is driving the growth of the cancer antibody drug conjugates market.

Major companies operating in the cancer antibody drug conjugates market are focusing on developing technologically advanced solutions such as cleavable tumor activated linker technology to enhance targeted delivery, treatment precision, and safety. Cleavable tumor activated linker technology refers to a specialized chemical system used in antibody drug conjugates that connects the cytotoxic drug to the antibody and releases it only when the antibody drug conjugate reaches the tumor microenvironment. For instance, in June 2025, Daiichi Sankyo Co. Ltd., a Japan based biopharmaceutical company, received United States Food and Drug Administration approval for Datroway datopotamab deruxtecan dlnk, a trophoblast cell surface antigen 2 TROP 2 directed antibody drug conjugate using a cleavable linker designed to treat adult patients with locally advanced or metastatic EGFR mutated non small cell lung cancer NSCLC who have received prior EGFR directed therapy and platinum based chemotherapy. The product features targeted payload release, improved tumour cell killing including bystander activity, and enhanced treatment tolerability. It improves precision in drug delivery and expands therapeutic options for difficult to treat solid tumours.

In December 2023, Pfizer Inc., a US based biopharmaceutical company, acquired Seagen Inc. for approximately forty three billion dollars. With this acquisition, Pfizer gains access to Seagen's antibody drug conjugate technology and its portfolio of approved antibody drug conjugate based cancer therapies, thereby expanding its oncology capabilities while improving therapeutic reach and pipeline strength in the cancer antibody drug conjugates industry. Seagen Inc. is a US based biotechnology company specializing in the development and commercialization of cancer antibody drug conjugates.

Major companies operating in the cancer antibody drug conjugates market are Johnson & Johnson, Roche Holding AG, Merck and Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Byondis BV, Adienne Pharma and Biotech SA, Helix BioPharma Corp., Adcytherix SAS

North America was the largest region in the cancer antibody drug conjugates market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer antibody drug conjugates report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cancer antibody drug conjugates market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cancer antibody drug conjugates market consists of sales of cytotoxic payloads, conjugation kits, targeted delivery agents, antibody-drug conjugates, tumor-targeting biomarkers, and companion diagnostic test kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Antibody Drug Conjugates Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer antibody drug conjugates market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for cancer antibody drug conjugates ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer antibody drug conjugates market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Cancer Antibody Drug Conjugates Market Characteristics

3. Cancer Antibody Drug Conjugates Market Trends And Strategies

4. Cancer Antibody Drug Conjugates Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Cancer Antibody Drug Conjugates Growth Analysis And Strategic Analysis Framework

6. Cancer Antibody Drug Conjugates Market Segmentation

7. Cancer Antibody Drug Conjugates Market Regional And Country Analysis

8. Asia-Pacific Cancer Antibody Drug Conjugates Market

9. China Cancer Antibody Drug Conjugates Market

10. India Cancer Antibody Drug Conjugates Market

11. Japan Cancer Antibody Drug Conjugates Market

12. Australia Cancer Antibody Drug Conjugates Market

13. Indonesia Cancer Antibody Drug Conjugates Market

14. South Korea Cancer Antibody Drug Conjugates Market

15. Western Europe Cancer Antibody Drug Conjugates Market

16. UK Cancer Antibody Drug Conjugates Market

17. Germany Cancer Antibody Drug Conjugates Market

18. France Cancer Antibody Drug Conjugates Market

19. Italy Cancer Antibody Drug Conjugates Market

20. Spain Cancer Antibody Drug Conjugates Market

21. Eastern Europe Cancer Antibody Drug Conjugates Market

22. Russia Cancer Antibody Drug Conjugates Market

23. North America Cancer Antibody Drug Conjugates Market

24. USA Cancer Antibody Drug Conjugates Market

25. Canada Cancer Antibody Drug Conjugates Market

26. South America Cancer Antibody Drug Conjugates Market

27. Brazil Cancer Antibody Drug Conjugates Market

28. Middle East Cancer Antibody Drug Conjugates Market

29. Africa Cancer Antibody Drug Conjugates Market

30. Cancer Antibody Drug Conjugates Market Competitive Landscape And Company Profiles

31. Cancer Antibody Drug Conjugates Market Other Major And Innovative Companies

32. Global Cancer Antibody Drug Conjugates Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Antibody Drug Conjugates Market

34. Recent Developments In The Cancer Antibody Drug Conjugates Market

35. Cancer Antibody Drug Conjugates Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기